B. Geibel

A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.

M. Trivedi, A. Patkar, Joseph Gao, 2013, The Journal of clinical psychiatry.

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy

D. Iosifescu, J. Reynolds, E. Sarkis, 2017, Journal of psychopharmacology.

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults

R. McIntyre, O. Brawman‐Mintzer, R. Weisler, 2018, Journal of clinical psychopharmacology.

Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.

R. McIntyre, O. Brawman‐Mintzer, R. Weisler, 2016, Journal of affective disorders.